The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation.

BACKGROUND Although estrogen has been shown to contribute to retardation of the development of coronary heart disease in premenopausal women, the efficacy of hormone replacement therapy for coronary heart disease prevention in women with established coronary heart disease remains controversial. Hence, additional research is needed to clarify the effects of hormone replacement therapy on the cardiovascular and clotting systems. We investigated the effect of estrogen on platelet aggregation induced by standard agonists (epinephrine and adenosine diphosphate), with and without the platelet antagonist aspirin. Furthermore, we analyzed our data according to the presence or absence of a prevalent polymorphism of the glycoprotein (GP) IIIa subunit of the platelet fibrinogen receptor GPIIb-IIIa, PlA2. METHODS AND RESULTS The effect of estrogen on aggregation of platelets was studied in healthy men (n = 20, 10 PlA1/A1 and 10 PlA1/A2) and premenopausal healthy women (n = 10, 5 PlA1/A1 and 5 PlA1/A2). The PlA1/A1 and PlA1/A2 individuals were matched for age and race. Platelet response to agonists was investigated in the presence of (1) estrogen (10(-11) to 10(-8) mol/L), (2) aspirin (0.056 to 56 micromol/L), (3) estrogen plus aspirin, and (4) estrogen plus ICI 182 780 (ICI, 10(-9) mol/L, an inhibitor of the estrogen receptor). We found that physiologic concentrations of estrogen strongly and significantly inhibited the aggregation of PlA1/A2 platelets (P<.005 for epinephrine and P<.05 for adenosine diphosphate, induced aggregation, respectively) in both men and women. Concentrations of estrogen that were 1000-fold greater were required to observe the same level of inhibition with PlA1/A1 platelets. In the presence of aspirin, estrogen failed to provide additional inhibitory effect on aggregation of both PlA1/A1 and PlA1/A2 platelets. The estrogen-specific inhibitor ICI blocked the effect of estrogen on aggregation, suggesting that this effect is mediated by the estrogen receptor. CONCLUSIONS Estrogen inhibits the aggregation of platelets, but such inhibition is highly dependent on the presence or absence of the PlA2 polymorphism of GPIIIa. However, in the presence of aspirin, the inhibitory effect of estrogen on aggregation was no longer detectable.

[1]  M. Mendelsohn,et al.  Protective effects of estrogen on the cardiovascular system. , 1999, The American journal of cardiology.

[2]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[3]  M. Furman,et al.  Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. , 2000, Circulation.

[4]  D. Levy,et al.  Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[5]  D. Grigoryev,et al.  The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[7]  P. Shaul,et al.  Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. , 1998, The Journal of clinical investigation.

[8]  G. Kajiyama,et al.  Effect of 17beta-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[9]  P. Bray,et al.  PlA2 polymorphism and efficacy of aspirin , 1998, The Lancet.

[10]  P. Bray,et al.  Gender Differences in Platelet GPIIb-IIIa Activation , 1997, Thrombosis and Haemostasis.

[11]  P. Ridker,et al.  PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis , 1997, The Lancet.

[12]  R. Fox,et al.  Refining the treatment of women with unstable angina—A randomized, double‐blind, comparative safety and efficacy evaluation of integrelin™ versus aspirin in the management of unstable angina , 1996 .

[13]  J. Weiss,et al.  A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. , 1996, The New England journal of medicine.

[14]  K. Blakemore,et al.  Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations , 1995, Transfusion.

[15]  A. Nurden.  Polymorphisms of Human Platelet Membrane Glycoproteins: Structure and Clinical Significance , 1995, Thrombosis and Haemostasis.

[16]  E. Barrett-Connor,et al.  Estrogen and coronary heart disease in women , 1991, JAMA.

[17]  R. Aster,et al.  The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. , 1989, The Journal of clinical investigation.